Skip to main content
SpringerLink
Log in

Immunohistochemical Markers for Prognosis of Ependymal Neoplasms

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Intracranial ependymomas are the third most common primary brain tumor in children. Although clinical and histological criteria for ependymoma prognosis are recognized, studies have reported contradictory results. Prognostic significance based on immunohistochemistry of ependymomas has been reported in a few studies. One-hundred and twelve patients with intracranial ependymomas were examined retrospectively for immuno-expression of various tumor-associated antigens and apoptosis. The results demonstrated significant preponderance of expression of the tenascin, vascular endothelial growth factor protein (VEGF), epidermal growth factor (EGFR) and p53 protein in high-grade tumors. Also high-grade ependymomas revealed more prominent labeling indices (LI) for proliferative marker Ki-S1 and apoptotic index (AI), and lower LI for cyclin-dependent kinase inhibitors p27/Kip1 and p14ARF. For low-grade ependymomas the progression-free survival time (PFS) was found to be significantly shorter for Ki-S1 LI>5%, and for tenascin, VEGF and EGFR positivity. For high-grade ependymomas PFS was found to be significantly reduced for p27 LI<20%, p14ARF LI<10%, for p53 positivity, and for AI<1%. The CART modeling process exhibited five final groups of ependymoma patients (1) low-grade and tenascin-negative; (2) low-grade and tenascin-positive; (3) high-grade and p53-negative with p14 LI>0%; (4) high-grade with combination of either p53 positivity and p14 LI>10% or p53 negativity and p14 LI<10%; (5) high-grade and p53-positive with p14 LI<10%. In summary, some immunohistochemical variables were found to be the strong predictors of ependymoma recurrence and they seem to be useful for assessing individual tumor prognosis in routinely processed biopsy specimens together with tumor grade. For histologically benign ependymomas immunohistochemical study should be focused on Ki-S1, tenascin, EGFR and VEGF evaluation, whereas p53 expression and number of p27, p14 and ISEL-positive nuclei will be of value in determining PFS from high-grade ependymomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. McLendon RE, Enterline DS, Tien RD, Thorstad WL, Bruner JM. Tumors of central neuroepithelial origin. In: Bigner DD, McLendon RE, Bruner JM (eds) Russel and Rubinstein's Pathology of Tumors of the Nervous System, vol 1, 6th edn, Arnold, London, 1998

    Google Scholar 

  2. Kleihues P, Cavenee WK (eds): Tumors of the Nervous System. Pathology and Genetics: World Health Organization International Classification of Tumours. IARC press, Lyon, 2000, pp 72-81

  3. Applegate GL, Marymont M: Intracranial ependymomas: a review. Cancer Invest 16: 588-593, 1998

    Google Scholar 

  4. Bouffet E, Perilongo G, Canete A, Massimino M: Intracranial ependymomas in children: a critical reviewof prognostic factors and a plea for cooperation. Med Pediatr Oncol 30: 319-329, 1998

    Google Scholar 

  5. Hamilton RL, Pollack IF: The molecular biology of ependymomas. Brain Pathol 7: 807-822, 1997

    Google Scholar 

  6. Rosenblum MK: Ependymal tumors: a review of their diagnostic surgical pathology. Pediatr Neurosurg 28: 160-165, 1998

    Google Scholar 

  7. Schiffer D, Giordana MT: Prognosis of ependymomas. Childs Nerv Syst 14: 357-361, 1998

    Google Scholar 

  8. Smyth MD, Horn BN, Russo C, Berger MS: Intracranial ependymomas of childhood: current management strategies. Pediatr Neurosurg 33: 138-150, 2000

    Google Scholar 

  9. Verstegen MJT, Bosch DA, Troost D: Treatment of ependymomas. Clinical and non-clinical factors influencing prognosis: a review. Br J Neurosurg 11: 542-553, 1997

    Google Scholar 

  10. Afra D, Muller W, Slowik F, Wickle O, Budka H, Turoczy L: Supratentorial lobar ependymomas: reports on the grading and survival periods in 80 cases, including 46 recurrences. Acta Neurochir (Wien) 69: 243-251, 1983

    Google Scholar 

  11. Bloom HJ, Glees J, Bell J, Ashley SE, Gorman C: The treatment and long-term prognosis of children with intracranial tumors: a study of 610 cases, 1950-1981. Int J Radiat Oncol Biol Phys 18: 723-745, 1990

    Google Scholar 

  12. Chiu JK, Woo SY, Ater J, Connelly J, Bruner JM, Maor MH, van Eys J, Oswald MJ, Shallenberger R: Intracranial ependymoma in children: analysis of prognostic factors. J Neuro-Oncol 13: 283-290, 1992

    Google Scholar 

  13. Ernestus RI, Schröder R, Stützer H, Klug N: The clinical and prognostic relevance of grading in intracranial ependymomas. Br J Neurosurg 11: 421-428, 1997

    Google Scholar 

  14. Ernestus RJ, Wilcke O, Schroder R: Intracranial ependymomas: prognostic aspects. Neurosurg Rev 12: 157-163, 1989

    Google Scholar 

  15. Ferrante L, Mastronardi L, Schettini G, Lunardi P, Fortuna A: Fourth ventricle ependymomas. A study of 20 cases with survival analysis. Acta Neurochir (Wien) 131: 67-74, 1994

    Google Scholar 

  16. Figarella-Branger D, Civatte M, Bouvier-Labit C, Gouvernet J, Gambarelli D, Gentet JC, Lena G, Choux M, Pellisier JF: Prognostic factors in intracranial ependymomas in children. J Neurosurg 93: 605-613, 2000

    Google Scholar 

  17. Foreman NK, Love S, Thorne R: Intracranial ependymomas: analysis of prognostic factors in a population-based series. Pediatr Neurosurg 24: 119-125, 1996

    Google Scholar 

  18. Gerszten PC, Pollack IF, Martínez AJ, Lo KH, Janosky J, Albright AL: Intracranial ependymomas of childhood. Lack of correlation of histopathology and clinical outcome. Pathol Res Pract 192: 515-522, 1996

    Google Scholar 

  19. Goldwein JW, Leahy JM, Packer RG: Intracranial ependymomas in children. Int J Radiat Oncol Biol Phys 19: 1497-1502, 1990

    Google Scholar 

  20. Good CD, Wade AM, Hayward RD, Phipps K, Michalski AJ, Harkness WFJ, Chong WK: Surveillance neuroimaging in childhood intracranial ependymoma: how effective, how often, and for how long. J Neurosurg 94: 27-32, 2001

    Google Scholar 

  21. Ho DM-T, Hsu C-Y, Wong T-T, Chiang H: A clinicopathologic study of 81 patients with ependymomas and proposal of diagnostic criteria for anaplastic ependymoma. J Neuro-Oncol 54: 77-85, 2001

    Google Scholar 

  22. Horn B, Heiderman R, Geyer R, Pollack I, Packer R, Goldwein J, Tomita T, Schomberg P, Ater J, Luchtman-Jose L, Rivlin K, Lamborn K, Prados M, Bollen A, Berger M, Dahl G, McNeil E, Patterson K, Shaw D, Kubalik M, Russo C: A multiinstitutional retrospective study of intracranial ependymoma in children: identification of risk factors. J Pediatr Hematol Oncol 21: 203-211, 1999

    Google Scholar 

  23. Jayawickreme DP, Hayward RD, Harkness WF: Intracranial ependymomas in childhood: a report of 24 cases followed for 5 years. Childs Nerv Syst 11: 409-413, 1995

    Google Scholar 

  24. Kovalic JJ, Flaris N, Grigsby PW, Pirkowski M, Simpson JR, Roth KA: Intracranial ependymoma long term outcome, patterns of failure. J Neuro-Oncol 15: 125-131, 1993

    Google Scholar 

  25. Lyons MK, Kelly PJ: Posterior fossa ependymomas: report of 30 cases and review of the literature. Neurosurgery 28: 659-664, 1991

    Google Scholar 

  26. McLaughlin MP, Marcus RBJ, Buatti JM, McCollough WM, Mickle PJ, Kedar A, Maria BL, Million RR: Ependymoma: results, prognostic factors and treatment recommendations. Int J Radiat Oncol Biol Phys 40: 845-850, 1998

    Google Scholar 

  27. Mork SJ, Loken AC: Ependymoma: a follow-up study of 101 cases. Cancer 40: 907-915, 1977

    Google Scholar 

  28. Nazar GB, Hoffman HJ, Becker LE, Jenkin D, Humphreys RP, Hendrick EB: Infratentorial ependymomas in childhood: prognostic factors and treatment. J Neurosurg 72: 408-417, 1990

    Google Scholar 

  29. Perilongo G, Massimino M, Sotti G, Benfontali T, Masiero L, Rigobello L, Carre L, Carli M, Lombardi F, Solero C, Sainati L, Canale V, del Prever AB, Giangaspero F, Andreussi L, Mazza C, Madon E: Analyses of prognostic factors in a retrospective review of 92 children with ependymoma: Italian Pediatric Neurooncology Group. Med Pediatr Oncol 29: 79-85, 1997

    Google Scholar 

  30. Pierre-Kahn A, Hirsch HJ, Roux FX: Intracranial ependymomas in childhood. Survival and function results of 47 cases. Childs Brain 10: 145-156, 1983

    Google Scholar 

  31. Pollack IF, Gerszten PC, Martinez AJ, Lo KH, Shultz B, Albright AL, Janosky J, Deutsch M: Intracranial ependymomas of childhood: long-term outcome and prognostic factors. Neurosurgery 37: 655-666, 1995

    Google Scholar 

  32. Rawlings CE, Giangaspero F, Burger PC, Bullard DE: Ependymomas: a clinicopathologic study. Surg Neurol 29: 271-281, 1988

    Google Scholar 

  33. Robertson PL, Zeltzer PM, Boyett JM, Rorke LB, Allen JC, Geyer R, Stanley Ph, Li H, Albright L, McGuire-Gullen P, Finlay JL, Stevens KR, Milstein JM, Packer RJ, Wisoff J, the Children's Cancer Group: Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group. J Neurosurg 88: 695-703, 1998

    Google Scholar 

  34. Ross GW, Rubinstein LJ: Lack of histopathological correlation of malignant ependymomas with postoperative survival. J Neurosurg 70: 31-36, 1989

    Google Scholar 

  35. Rousseau P, Habrand JL, Sarrazin D, Kalifa C, Terrier-Lacombe MJ, Rekacewicz C, Rey A: Treatment of intracranial ependymomas of children: review of 15-year experience. Int J Radiat Oncol Biol Phys 28: 381-386, 1994

    Google Scholar 

  36. Sala F, Talacchi A, Mazza C, Prisco R, Chimenton C, Bricolo A: Prognostic factors in childhood intracranial ependymomas: the role of age and tumor location. Pediatr Neursorg 28: 135-142, 1998

    Google Scholar 

  37. Schiffer D, Chio A, Cravioto H, Giordana MT, Migheli A, Soffietti R, Vigliani MC: Ependymoma: internal correlations among pathological signs: the anaplastic variant. Neurosurgery 29: 206-210, 1991

    Google Scholar 

  38. Schiffer D, Chio A, Giordana MT, Migheli A, Palma L, Pollo B, Soffietti R, Tribolo A: Histologic prognostic factors in ependymoma. Child Nerv Syst 7: 177-182, 1991

    Google Scholar 

  39. Vanuytsel LJ, Bessel EM, Ashley SE, Bloom HJ, Brada M: Intracranial ependymoma: long-term results of a policy of surgery and radiotherapy. Int J Radiat Oncol Biol Phys 23: 313-319, 1992

    Google Scholar 

  40. Choi Y-L, Chi JG, Suh Y-L: CD99 immunoreactivity in ependymoma. Appl Immunohistochem Mol Morphol 9: 125-129, 2001

    Google Scholar 

  41. Packer JR, Armstrong DL, Strother D, Rudman DM, Dauser RC, Laurent JP, Deyd J, Rouah PE: Antineuronal nuclei immunohistochemical staining patterns in childhood ependymomas. J Child Neurol 16: 548-552, 2001

    Google Scholar 

  42. Asai A, Hoshino T, Edwards MS, Davis RL: Predicting the recurrence of ependymomas from the bromodeoxyuridine labeling index. Childs Nerv Syst 8: 273-278, 1992

    Google Scholar 

  43. Bennetto L, Foreman N, Harding B, Hayward R, Ironside J, Love S, Ellison D: Ki-67 labelling index is a prognostic indicator in childhood posterior fossa ependymomas. Neuropathol Appl Neurobiol 24: 434-440, 1998

    Google Scholar 

  44. Bortolotto S, Chiado-Piat L, Cavalla P, Bosone I, Mauro A, Schiffer D: CDKN2A/p16 in ependymomas. J Neuro-Oncol 54: 9-13, 2001

    Google Scholar 

  45. Figarella-Branger D, Gambarelli D, Dollo C: Infratentorial ependymomas of childhood. Correlation between histological features, immunohistological phenotype, silver nucleolar organizer region staining values and postoperative survival in 16 cases. Acta Neuropathol (Berl) 82: 208-216, 1991

    Google Scholar 

  46. Prayson RA: Cyclin D1 and MIB-1 immunohistochemistry in ependymomas: a study of 41 cases. Am J Clin Pathol 110: 629-634, 1998

    Google Scholar 

  47. Prayson RA: Clinicopathologic study of 61 patients with ependymoma including MIB-1 immunohistochemistry. Ann Diagn Pathol 3: 11-18, 1999

    Google Scholar 

  48. Rezai A, Woo HH, Lee M, Cohen H, Zagzag D, Epstein FJ: Disseminated ependymomas of the central nervous system. J Neurosurg 85: 618-624, 1996

    Google Scholar 

  49. Ritter AM, Hess KR, McLendon RE, Langford LA: Ependymomas: MIB-1 proliferation index and survival. J Neuro-Oncol 40: 51-57, 1998

    Google Scholar 

  50. Rushing EJ, Brown DF, Hladic CL, Risser RC, Mickey BE, White CL: Correlation of bcl-2, p53 and MIB-1 expression with ependymoma grade and subtypes. Mod Pathol 11: 464-467, 1998

    Google Scholar 

  51. Rushing EJ, Yashima K, Brown DF, White III CL, Shay JW, Risser RC, Gazdar AF: Expression of telomerase RNA component correlates with the MIB-1 proliferation index in ependymomas. J Neuropathol Exp Neurol 56: 1142-1156, 1997

    Google Scholar 

  52. Schiffer D, Chio A, Giordana MT, Migheli A, Soffietti R: Proliferating cell nuclear antigen expression in brain tumors, and its prognostic role in ependymomas: an immunohistochemical study. Acta Neuropathol (Berl) 85: 495-502, 1993

    Google Scholar 

  53. Schroder R, Ploner C, Ernestus RG: The growth potential of ependymomas with varying grades of malignancy measures with the KI-67 labeling index and mitotic index. Neurosurg Rev 16: 145-150, 1993

    Google Scholar 

  54. Verstegen MJT, Troost D, Leenstra S, Ijlst-Keizers H, Bosch DA: Proliferation-and apoptosis-related proteins in intracranial ependymomas: an immunohistochemical analysis. J Neuro-Oncol 56: 21-28, 2002

    Google Scholar 

  55. Bijlsma EK, Voesten AM, Bijleveld EH, Troost D, Westerveld A, Merel P, Thomas G, Hulsebos TG: Molecular analysis of genetic changes in ependymomas. Genes Chromosomes Cancer 13: 272-277, 1995

    Google Scholar 

  56. Ebert C, von Haken M, Meyer-Puttlitz B, Wiestler OD, Reifenberger G, Pietsch T, von Deimling A: Molecular genetic analysis of ependymal tumors: NF2 mutation and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. Am J Pathol 155: 627-632, 1999

    Google Scholar 

  57. Fink KL, Rushing EJ, Schold SC, Nisen PD: Infrequency of p53 gene mutation in ependymomas. J Neuro-Oncol 27: 111-115, 1996

    Google Scholar 

  58. Haken von HM, White EC, Daneshvar SL, Sih S, Choi E, Kalra R, Cogen PH: Molecular genetic analysis of chromosome arm 17p and chromosome arm 22q DNA sequences in sporadic pediatric ependymomas. Genes Chromosomes Cancer 17: 37-44, 1996

    Google Scholar 

  59. Hirose Y, Aldape K, Bollen A, James CD, Brat D, Lamborn K, Berger M, Feuerstein BG: Chromosomal abnormalities subdivided ependymal tumors into clinically relevant groups. Am J Pathol 159: 1137-1143, 2001

    Google Scholar 

  60. Hulsebos TJM, Oskam NT, Bijleveld EH, Westerveld A, Hermsen MA, van den Ouweland, Hamel BC, Tijssen CC: Evidence for an ependymoma tumor suppressor gene in chromosome region 22pter-22q11.2. Br J Cancer 81: 1150-1154, 1999

    Google Scholar 

  61. Kramer DL, Parmiter AH, Rorke LB: Molecular cytogenetic studies of pediatric ependymomas. J Neuro-Oncol 37: 25-33, 1998

    Google Scholar 

  62. Kraus JA, de Millas W, Sorensen N, Herbold C, Schichor C, Tonn JC, Wiestler OD, Deimling von A, Pietsch T: Indication for a tumor suppressor gene at 22q11 involved in the pathogenesis of ependymal tumors and distinct form hSNF5/INI1. Acta Neuropathol (Berl) 102: 69-74, 2001

    Google Scholar 

  63. Lamszus K, Lachenmayer L, Heinemann U, Kluwe L, Finckh U, Hoppner W, Stavrou D, Fillbrandt R, Westphal M: Molecular genetic alterations on chromosomes 11 and 22 in ependymomas. Int J Cancer 91: 803-808, 2001

    Google Scholar 

  64. Mazewski C, Soukup S, Ballard E, Gotwals B, Lampkin B: Karyotype studies in 18 ependymomas with literature review of 107 cases. Cancer Genet Cytogenet 113: 1-8, 1999

    Google Scholar 

  65. Scheil S, Bruderflein S, Eicker M, Herms J, Herold-Mende C, Steiner H, Berth TFE, Moller P: Low-frequency of chromosomal imbalances in anaplastic ependymomas as detected by comparative genomic hybridization. Brain Pathol 11: 133-143, 2001

    Google Scholar 

  66. Tominaga T, Kayama T, Kumabe T, Sonoda Y, Yoshimoto T: Anaplastic ependymomas: clinical features and tumour suppressor gene p53 analysis. Acta Neurochir (Wien) 135: 163-170, 1995

    Google Scholar 

  67. Tong CY, Zheng PP, Pang JC, Poon WC, Chang AR, Ng HK: Identification of novel regions of allelic loss in ependymomas by high-resolution allelotyping with 384 microsatellite markers. J Neurosurg 95: 9-14, 2001

    Google Scholar 

  68. Vagner-Capodano AM, Zattara-Cannoni H, Gambarelli D, Figarrela-Branger D, Lena G, Dufour H, Grisoli F, Choux M: Cytogenetic study of 33 ependymomas. Cancer Genet Cytogenet 115: 96-99, 1999

    Google Scholar 

  69. Ward S, Harding B, Wilkins P, Harkness W, Hayward R, Darling JL, Thomas DG: Gain of 1q and loss of 22 are the most common changes detected by comparative genomic hybridization in paediatric ependymomas. Genes Chromosomes Cancer 32: 59-66, 2001

    Google Scholar 

  70. Zheng BP, Pang JCS, Hui ABY: Comparative genomic hybridization detects losses of chromosomes 22 and 16 as the most common recurrent genetic alterations in primary ependymomas. Cancer Genet Cytogenet 122: 18-25, 2000

    Google Scholar 

  71. Korshunov A, Golanov A, Timirgaz V: Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases. J Neurol Sci 177: 72-82, 2000

    Google Scholar 

  72. Korshunov A, Golanov A, Timirgaz V: p14ARF protein (FL-132) immunoreactivity in intracranial ependymomas and its prognostic significance. An analysis of 103 cases. Acta Neuropathol (Berl) 102: 271-277, 2001.

    Google Scholar 

  73. Korshunov A, Sycheva R, Timirgaz V, Golanov A: Prognostic value of immunoexpression of the chemoresistance-related proteins in ependymomas. An analysis 76 cases. J Neuro-Oncol 45: 219-227, 1999

    Google Scholar 

  74. Korshunov A, Timirgaz V, Golanov A: Prognostic value of aberrant p53 immunoexpression for the recurrence of ependymoma. An analysis of 76 cases. Neuropathology 19: 380-385, 1999

    Google Scholar 

  75. Korshunov A, Golanov A, Sycheva R, Pronin I: Prognostic value of tumour-associated antigens immunoreactivity and apoptosis in cerebral glioblastomas: an analysis of 168 cases. J Clin Pathol 52: 574-580, 1999

    Google Scholar 

  76. Kotylo PK, Robertson PB, Fineberg NS, Azzarelli B, Jakacki R: Flow cytometric DNA analysis of pediatric intracranial ependymomas. Arch Pathol Lab Med 121: 1255-1258, 1997

    Google Scholar 

  77. Holden JA, Townsend JJ: DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: correlation with MIB1 expression and patient survival. Mod Pathol 12: 1094-1100, 1999

    Google Scholar 

  78. Taniguchi K, Wakabayashi T, Yoshida T, Mizuno M, Yoshikawa K, Kikuchi A, Nakashima N, Yoshida J: Immunohistochemical staining of DNA topoisomerase II a in human gliomas. J Neurosurg 91: 477-482, 1999

    Google Scholar 

  79. Castellani P, Dorcaratto A, Siri A: Tenascin distribution in human brain tumours. Acta Neurochir (Wien) 136: 44-50, 1995

    Google Scholar 

  80. Hasegawa K, Yoshida T, Matsumoto K, Katsuta K, Waga S, Sakakura T: Differential expression of tenascin-C and tenascin-X in human astrocytomas. Acta Neuropathol (Berl) 93: 431-437, 1997

    Google Scholar 

  81. Chan ASY, Leung SY, Wong MP, Yuen TS, Cheung N, Fan YW, Chung LP: Expression of vascular endothelial growth factor and its receptors in anaplastic progression of astrocytoma, oligodendroglioma and ependymoma. Am J Surg Pathol 22: 816-826, 1998

    Google Scholar 

  82. Pietsch T, Valter MM, Wolf HK, von Deimling A, Huang HJ, Cavenee WK, Wiestler OD: Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol (Berl) 93: 109-117, 1997

    Google Scholar 

  83. Oehring RD, Miletic M, Valter MM, Pietsch T, Newmann, Fimmers R, Schlegel U: Vascular endothelial growth factor (VEGF) in astrocytic gliomas-A prognostic factor? J Neuro-Oncol 45: 117-125, 1999

    Google Scholar 

  84. Abdulrauf SI, Edvardsen K, Ho KL, Yang XY, Rock JP, Rosenblum ML: Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade gliomas. J Neurosurg 88: 513-520, 1998

    Google Scholar 

  85. Waha A, Baumann A, Wolf HK, Fimmers R, Neumann J, Kindermann D, Astrahantseff K, Blumke A, von Deimling A, Schlegel U: Lack of prognostic relevance of alterations in epidermal growth factor receptor-transforming growth factor a pathway in human astrocytic gliomas. J Neurosurg 85: 634-641, 1996

    Google Scholar 

  86. Diedrich U, Lucius J, Baron E, Behnke J, Pabst B, Zoll V: Distribution of epidermal growth factor receptor gene amplification in brain tumours and correlation to prognosis. J Neurol 242: 638-688, 1995

    Google Scholar 

  87. Hall WA, Merrill MJ, Walbridje S, Youle RJ: Epidermal growth factor receptors in ependymomas and other brain tumors. J Neurosurg 72: 641-646, 1990

    Google Scholar 

  88. Nieder C, Petersen S, Petersen C, Thames HD: The challenge of p53 as prognostic and predictive factor in gliomas. Cancer Treat Rev 26: 67-73, 2000

    Google Scholar 

  89. Rainov NG, Dobberstein KU, Bahn H, Holzhausen HJ, Lautenschläger C, Heidecke V, Burkert W: Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neuro-Oncol 35: 13-28, 1997

    Google Scholar 

  90. Tong CY, Ng HK, Pang JC, Hul AB, Ko HC, Lee JC: Molecular genetic analysis of non-astrocytic gliomas. Histopathology 34: 331-341, 1999

    Google Scholar 

  91. Suzuki SO, Iwaki T: Amplification and overexpression of mdm2 gene in ependymomas. Mod Pathol 13: 548-553, 2000

    Google Scholar 

  92. Mainprize TG, Taylor MD, Rutka JT, Dirks PB: Cip/Kip cell-cycle inhibitors: a neuro-oncological perspective. J Neuro-Oncol 51:205-218, 2001

    Google Scholar 

  93. Alleyne GH Jr, He J, Yang J, Hunter SB, Cotsonis G, James CD, Olson JJ: Analysis of cyclin dependent kinase inhibitors in malignant astrocytomas. Int J Oncol 14: 1111-1116, 1999

    Google Scholar 

  94. Fuse T, Tanikawa M, Nakanishi M: p27Kip1 expression by contact inhibition as a prognostic index of human glioma. J Neurochem 74: 1393-1399, 2000

    Google Scholar 

  95. Mizumatsu S, Tamiya T, Ono Y, Abe T, Matsumoto K, Furuta T, Ohmoto T: Expression of cell cycle regulator p27/kip1 is correlated with survival of patients with astrocytoma. Clin Cancer Res 5: 551-557, 1999

    Google Scholar 

  96. Piva R, Cavalla S, Bortolotto S, Cordera S, Richiardi P, Schiffer D: p27/kip1 expression in human astrocytic gliomas. Neurosci Lett 234: 127-130, 1997

    Google Scholar 

  97. Tamiya T, Mizumatsu S, Ono Y, Abe T, Matsumoto K, Furuta T, Ohmoto T: High cyclin E/lowp27kip1 expression is associated with poor prognosis in astrocytomas. Acta Neuropathol (Berl) 101: 334-340, 2001

    Google Scholar 

  98. Schiffer D, Bortolotto S, Bossone I, Cancelli I, Cavalla P, Schiffer P, Piva R: Cell-cycle inhibitor p27/kip1 expression in non-astrocytic and non-oligodendrocytic human nervous sytem tumors. Neurosci Lett 264: 29-32, 1999

    Google Scholar 

  99. Khalid MH, Yagi N, Hiura T, Shibata S: Immunohistochemical analysis of p53 and p21 in human primary glioblastomas in relation to proliferative potential and apoptosis. Brain Tumor Pathol 15: 89-94, 1998

    Google Scholar 

  100. Kirla R, Salminen E, Huhtala S: Prognostic value of the expression of tumor suppressor genes p53, p21, p16, and pRb, and Ki-67 labelling in high-grade astrocytomas treated with radiotherapy. J Neuro-Oncol 46: 71-80, 2000

    Google Scholar 

  101. Korkolopoulou P, Kouzelis K, Christodoulou P, Papanikolaou A, Thomas-Tsagli E: Expression of retinoblastoma gene product and p21 (WAF1/Cip1) protein in gliomas: correlation with proliferation markers, p53 expression and survival. Acta Neuropathol (Berl) 95: 617-624, 1998

    Google Scholar 

  102. Li YJ, Hoang-Xuan K, Zhou XP, Sanson M, Mokhtari K, Faillot T, Cornu P, Poisson M, Thomas G, Hamelin R: Analysis of the p21 gene in gliomas. J Neuro-Oncol 40: 107-111, 1998

    Google Scholar 

  103. Ono Y, Tamiya T, Ichikawa T: Accumulation of wildtype p53 in astrocytomas is associated with increased p21 expression. Acta Neuropathol (Berl) 94: 21-27, 1997

    Google Scholar 

  104. Ivanchuk SM, Mondal S, Dirks PB, Rutka JT: The INK4A/ARF locus: Role in cell cycle control and apoptosis and implication fro glioma growth. J Neuro-Oncol 51: 219-229, 2001

    Google Scholar 

  105. Fulci G, Labuhn M, Maier D, Lachat Y, Hausmann O, Hegi ME, Janzer RC, Merlo A, Van Meir EG: p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene 19: 3816-3822, 2000

    Google Scholar 

  106. Ichimura K, Bolin MB, Goike HM, Schmidt EE, Moshref A, Collins VP: Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 60: 417-424, 2000

    Google Scholar 

  107. Newcomb EW, Alonso M, Sung T, Miller DC: Incidence of p14ARF gene deletion in high-grade adult and pediatric astrocytomas. Hum Pathol 31: 115-119, 2000

    Google Scholar 

  108. Nakamura M, Watanabe T, Klangby U, Asker C, Wilman K, Yonekawa Y, Kleihues P, Ohgaki H: p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 11: 159-168, 2001

    Google Scholar 

  109. Watanabe T, Nakamura M, Yonekawa Y, Kleihues P, Ohgaki H: Promoter hypermethylation and homozygous deletion of p14ARF and p16INK4a genes in oligodendrogliomas. Acta Neuropathol (Berl) 101: 185-189, 2001

    Google Scholar 

  110. Lindstrom MS, Klangby U, Inoue R, Wiman KG, Asker CE: Immunolocalization of human p14(ARF) to the granular component of the interphase nucleolus. Exp Cell Res 256: 400-410, 2000

    Google Scholar 

  111. Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, Baylin SB, Herman JG: Hypermethylation-associated inactivation of p14 (ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res 60: 129-133, 2000

    Google Scholar 

  112. Gazzeri S, Della Valle V, Chaussade L, Brambilla C, Larsen CJ, Brambilla E: The human p19ARF protein encoded by the b transcript of the p16INK4a gene is frequently loss in small cell lung cancer. Cancer Res 58: 3926-3931, 1998

    Google Scholar 

  113. Piva R, Cancelli I, Cavalla S, Bortolotto S, Dominguez J, Draetta JF, Schiffer D: Proteasome-dependent degradation of p27/kip1 in gliomas. J Neuropathol Exp Neurol 58: 691-696, 1999

    Google Scholar 

  114. Robertson KD, Jones PA: The human ARF cell cycle regulatore gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol Cell Biol 18: 6457-6473, 1998

    Google Scholar 

  115. Savitz SI, Rosenbaum DM: Apoptosis in neurological desease. Neurosurgery 42: 555-574, 1998

    Google Scholar 

  116. Deininger MH, Grote E, Wickboldt J, Meyermann R: Distinct radiochemotherapy protocols differentially influence cellular proliferation and expression of p53 and bcl-2 in glioblastoma multiforme relapses in vivo. J Neuro-Oncol 48: 121-129, 2000

    Google Scholar 

  117. Heesters MAAM, Koudstaal J, Go KG, Molenaar WM: Analysis of proliferation and apoptosis in brain gliomas: prognostic and clinical value. J Neuro-Oncol 44: 255-266, 1999

    Google Scholar 

  118. Korkolopoulou PA, Konstantinidou AE, Patsorius ES, Christodoulou PN, Thomas-Tsagli EA, Davaris PS: Detection of apoptotic cells in archival tissue from diffuse astrocytomas using a monoclonal antibody to single-stranded DNA. J Pathol 193: 377-382, 2001

    Google Scholar 

  119. Hukin J, Epstein F, Lefton D, Allen J: Treatment of intracranial ependymoma by surgery alone. Pediatr Neurosurg 29: 40-45, 1998

    Google Scholar 

  120. Kedar A: Chemotherapy for pediatric brain tumors. Semin Pediatr Neurol 4: 320-332, 1997

    Google Scholar 

  121. Needle MN, Goldwein JW, Grass J, Cnaan A, Bergman I, Molloy P, Sutton L, Zhao H, Garvin JH Jr, Phillips PC: Adjuvant chemotherapy for the teratment of intracranial ependymoma of childhood. Cancer 80: 341-347, 1997

    Google Scholar 

  122. Siffert J, Allen JC: Chemotherapy in recurrent ependymoma. Pediatr Neurosurg 28: 314-319, 1998

    Google Scholar 

  123. Souweidane MM, Bouffet E, Finlay J: The role of chemotherapy in newly diagnosed ependymoma in childhood. Pediatr Neurosurg 28: 273-278, 1998

    Google Scholar 

  124. Timmermann B, Kortmann RD, Kuhl J, Meisner C, Slavc I, Pietsch T, Bamberg M: Combined postoperative irradiation and chemotherapy for anaplastic ependymomas in childhood: results of the german prospective trials HIT88/89 and HIT 91. Int J Radiat Oncol Biol Phys 46: 287-295, 2000

    Google Scholar 

  125. Chou PM, Barquin N, Gonzales Crussi F, Ridaura Sanz C, Tomita T, Reyes Mugica M: Ependymomas in children express the multidrug resistance gene: immunohistochemical and molecular biology study. Pediatr Pathol Lab Med 16: 551-561, 1996

    Google Scholar 

  126. Geddes JF, Vowle GH, Ashmore SM, Cockburn HA, Darling JL: Detection of multidrug resistance gene product (P-glycoprotein) expression in ependymomas. Neuropathol Appl Neurobiol 20: 118-121, 1994

    Google Scholar 

  127. Nagane M, Lin H, Cavenee WK, Huang HJ: Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications. Cancer Lett 162: 17-21, 2001

    Google Scholar 

  128. Puduvalli VK, Sawaya R: Antiangiogenesis-theraupeutic strategies and clinical implications for brain tumors. J Neuro-Oncol 50: 189-200, 2000

    Google Scholar 

  129. Engelhard HH: Gene therapy for brain tumors: the fundamentals. Surg Neurol 54: 3-9, 2000

    Google Scholar 

  130. Fueyo J, Gomez-Manzano C, Liu T-J, Yung WKA: Delivery of cell cycle genes to block astrocytoma growth. J Neuro-Oncol 51: 277-287, 2001

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neuropathology, Neurosurgical NN Burdenko Institute, Moscow, Russia

    Andrey Korshunov

  2. Department of Neuro-Oncological Surgery, Neurosurgical NN Burdenko Institute, Moscow, Russia

    Andrey Golanov & Valery Timirgaz

Authors
  1. Andrey Korshunov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrey Golanov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Valery Timirgaz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Korshunov, A., Golanov, A. & Timirgaz, V. Immunohistochemical Markers for Prognosis of Ependymal Neoplasms. J Neurooncol 58, 255–270 (2002). https://doi.org/10.1023/A:1016222202230

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1016222202230

Search

Navigation